Top

Published in:

Open Access 01-12-2021 | Coronavirus | Letter to the Editor

Risk of heparinoid use in cosmetics and moisturizers in individuals vaccinated against severe acute respiratory syndrome coronavirus 2

Author: Kenji Yamamoto

Published in: Thrombosis Journal | Issue 1/2021

Abstract

Recently, heparin-induced thrombocytopenia (HIT) after vaccination with the vaccines manufactured by AstraZeneca and Pfizer–BioNTech has been published in the New England Journal of Medicine. These reports state that heparin was not used around the vaccination period in all cases. HIT after vaccination is more common in women; thus, heparinoid use can be suspected to induce HIT.

Lei Y, Zhang J, Schiavon CR, He M, Chen L, Shen H, et al. SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2. Cir Res. 2021;128:1323–6. doi:https://doi.org/10.1161/CIRCRESAHA.121.318902.CrossRef

Schultz NH, Sørvoll IH, Michelsen AE, Weisser K, Kyrle PA, Eichinger S. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384:2124–30. doi:https://doi.org/10.1056/NEJMoa2104882.CrossRef

Cines DB, Bussel JB. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med. 2021;384:2254–6. doi:https://doi.org/10.1056/NEJMe2106315.CrossRefPubMed

Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. Engl J Med. 2021;384:2092–01.CrossRef

Douxfils J, Favresse J, Dogné JM, Lecompte T, Susen S, Cordonnier C, et al. Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. Thromb Res. 2021;203:163–71. doi:https://doi.org/10.1016/j.thromres.2021.05.010.CrossRefPubMedPubMedCentral

Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med. 2021. doi:https://doi.org/10.1056/NEJMoa2109908.CrossRefPubMed

Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006;108:2937–41. doi:https://doi.org/10.1182/blood-2005-11-012450.CrossRefPubMed

Mimura W, Akazawa M. The association between internet searches and moisturizer prescription in Japan: Retrospective observational study. JMIR Public Health Surveill. 2019;5:e13212. doi:https://doi.org/10.2196/13212.CrossRefPubMedPubMedCentral

Chong BH, Ismail F, Cade J, Gallus AS, Gordon S, Chesterman CN. Heparin-induced thrombocytopenia: Studies with a new low molecular weight heparinoid, Org 10172. Blood. 1989;73:1592–6.CrossRef

10.

Kumokawa T, Hirata K, Sato K, Kano S. Dermal absorption of mucopolysaccharide polysulfate (heparinoid) in human and minipig. Arzneimittelforschung. 2011;61:85–91.CrossRef

11.

Yamamoto K. Five of the important preventive measures against the exacerbation of coronavirus disease. Anaesthesiol Intensive Ther. 2021;53:1–2. doi:https://doi.org/10.5114/ait.2021.108581.CrossRef

Title: Risk of heparinoid use in cosmetics and moisturizers in individuals vaccinated against severe acute respiratory syndrome coronavirus 2
Author: Kenji Yamamoto
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Coronavirus
Vaccination
SARS-CoV-2
Thrombocytopenia
COVID-19
Heparinoide
Heparin
Heparin-Induced Thrombocytopenia
Published in: Thrombosis Journal / Issue 1/2021
Electronic ISSN: 1477-9560
DOI: https://doi.org/10.1186/s12959-021-00320-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Endovascular revascularization strategies using catheter-based thrombectomy versus conventional catheter-directed thrombolysis for acute limb ischemia

Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study

The evolution of clot strength in critically-ill COVID-19 patients: a prospective observational thromboelastography study

Successful venous thromboprophylaxis in a patient with vaccine-induced immune thrombotic thrombocytopenia (VITT): a case report of the first reported case in Thailand

Monitoring coagulation-fibrinolysis activation prompted timely diagnosis of hemophagocytic lymphohistiocytosis-related disseminated intravascular coagulation

Autopsy and statistical evidence of disturbed hemostasis progress in COVID-19: medical records from 407 patients

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials